Boston Partners’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-29,977
| Closed | -$858K | – | 748 |
|
|
2024
Q2 | $858K | Buy |
29,977
+8,907
| +42% | +$255K | ﹤0.01% | 609 |
|
|
2024
Q1 | $616K | Sell |
21,070
-36,748
| -64% | -$1.07M | ﹤0.01% | 660 |
|
|
2023
Q4 | $1.95M | Sell |
57,818
-50,691
| -47% | -$1.71M | ﹤0.01% | 502 |
|
|
2023
Q3 | $3.33M | Buy |
108,509
+55,679
| +105% | +$1.71M | ﹤0.01% | 441 |
|
|
2023
Q2 | $2.12M | Sell |
52,830
-24,880
| -32% | -$997K | ﹤0.01% | 474 |
|
|
2023
Q1 | $3.17M | Buy |
77,710
+156
| +0.2% | +$6.37K | ﹤0.01% | 429 |
|
|
2022
Q4 | $2.99M | Sell |
77,554
-23,035
| -23% | -$889K | ﹤0.01% | 419 |
|
|
2022
Q3 | $5.35M | Buy |
100,589
+56,282
| +127% | +$2.99M | 0.01% | 388 |
|
|
2022
Q2 | $2.58M | Buy |
44,307
+362
| +0.8% | +$21.1K | ﹤0.01% | 419 |
|
|
2022
Q1 | $3.35M | Buy |
43,945
+32,351
| +279% | +$2.47M | ﹤0.01% | 419 |
|
|
2021
Q4 | $698K | Buy |
+11,594
| New | +$698K | ﹤0.01% | 577 |
|